Back to News
Market Impact: 0.2
Alector Signs Global License Deal With Genentech For AL050
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Alector entered into an exclusive global licensing agreement with Genentech for its AL050 program. The announcement did not disclose financial terms or other deal details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ALEC0.55
More News
- Why is Alector stock surging today?
- Samsung, SK Hynix shares drop as Q3 earnings loom
- CH Robinson to Buy RXO for $5.8B in Bet on AI Model
- BPCE acquires 7% stake in Spain’s Banco Sabadell
- Wells Fargo gets a bold upgrade ahead of earnings. Why the stock can play catch-up
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status